Shots:
- Zentiva has entered into a license & supply agreement with Lupin to commercialize Lupin’s TNF-alpha inhibitor biosimilar across multiple global markets
- Zentiva will lead commercialization outside the US & Canada, mainly in EU & CIS, while Lupin will handle development, manufacturing, & supply in agreed territories & commercialization in the remaining territories, incl. the US & Canada
- As per the deal, Lupin will receive a $10M upfront & ~$50M in development & regulatory milestones, with both companies sharing profits from defined markets. Also, both parties will invest in the biosimilar’s development
Ref: PRNewswire | Image: Lupin & Zentiva| Press Release
Related News:- Lupin Collaborates with SteinCares to Commercialize Ranibizumab Biosimilar in Latin America
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
